18 completed, 17 recruiting, 5 terminated, 5 unknown. 52 Phase 1, 16 Phase 2.
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation CD45RA-depleted DLI - Hematologic Malignancy, Haplo-identical HCT | Phase 1 | Not yet recruiting | Ruijin Hospital | 30 | 2026-07-01 | 2026-06-29 |
| Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-05 | 2026-06-08 |
| CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy, Haplo-identical HCT | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 30 | 2026-06-01 | 2026-06-23 |
| TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Thymoglobulin, Cyclophosphamide, Fludarabine - Hematologic Malignancy | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-09-25 | 2026-06-02 |
| Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies G-CSF, Decitabine, Venetoclax - Myeloid Malignancy, Hematologic Malignancy | Phase 1 | Recruiting | University of Alabama at Birmingham | 20 | 2025-07-17 | 2026-03-04 |
| CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 80 | 2024-12-31 | 2024-12-06 |
| Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology - Hematologic Malignancy, Haplo-identical Stem Cell Transplantation | Phase 1 | Recruiting | University Hospital, Geneva | 12 | 2024-11-26 | 2025-02-13 |
| Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia WBC100 QD - AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia | Phase 1 | Recruiting | Hangzhou Weben Pharma Co., Ltd | 36 | 2024-11-03 | 2026-10-16 |
| CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous) - Hematologic Malignancy, ALL, Childhood | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 18 | 2024-10-16 | 2026-01-23 |
| Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes - Cancer, Solid Tumor | Phase 1 | Not yet recruiting | Zhejiang Provincial People's Hospital | 39 | 2024-07-31 | 2024-07-30 |
| TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies TGRX-1942 - Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 | Recruiting | Shenzhen TargetRx Co., Ltd. | 90 | 2024-07-08 | 2025-02-24 |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) TRX103 - Hematologic Malignancy, GvHD | Phase 1 | Recruiting | Tr1X, Inc. | 36 | 2024-04-08 | 2025-04-15 |
| TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies TGRX-814 - Hematologic Malignancy, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Shenzhen TargetRx Co., Ltd. | 30 | 2024-03-06 | 2024-04-10 |
| Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies autologous hematopoietic stem cells added to planned CAR T - Hematologic Malignancy, Large B-cell Lymphoma | Phase 1 | Recruiting | Joshua Sasine, MD, PhD | 20 | 2024-03-02 | 2026-08-10 |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Ziftomenib, Fludarabine, Idarubicin - AML, AML With Mutated NPM1 | Phase 1 | Recruiting | Kura Oncology, Inc. | 171 | 2024-02-22 | 2026-08-20 |
| A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy TQB3909 tablets, TQB3702 tablets - Hematologic Malignancy | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 208 | 2024-01-01 | 2024-01-18 |
| A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML BC3402 Injection - Hematologic Malignancy | Phase 1 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 13 | 2023-07-06 | 2023-07-24 |
| CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | University Hospital Tuebingen | 60 | 2023-04-27 | 2025-04-27 |
| A Phase I Study of BR108 in Hematological Malignancies BR108 injection - Hematologic Malignancy | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 8 | 2023-03-18 | 2025-11-21 |
Showing 20 of 52. Sign in to see all of them.
Hematologic Neoplasms (52) · Leukemia, Myeloid, Acute (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Myelodysplastic Syndromes (8) · Lymphoma (7) · Leukemia (5) · Lymphoma, Non-Hodgkin (5) · Multiple Myeloma (5) · Recurrence (5) · Hodgkin Disease (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Anemia, Refractory, with Excess of Blasts (3) · Anemia, Aplastic (2) · Graft vs Host Disease (2)
Hematologic Diseases (52) · Hemic and Lymphatic Diseases (52) · Neoplasms by Site (52) · Neoplasms (50) · Neoplasms by Histologic Type (23) · Immune System Diseases (19) · Immunoproliferative Disorders (18) · Lymphatic Diseases (18) · Lymphoproliferative Disorders (18) · Leukemia (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Leukemia, Myeloid (13) · Bone Marrow Diseases (12) · Leukemia, Lymphoid (12)
fludarabine (9) · Cyclophosphamide (7) · Cytarabine (3) · Granulocyte Colony-Stimulating Factor (3) · Mesna (3) · fludarabine phosphate (3) · Dexamethasone (2) · Filgrastim (2) · Melphalan (2) · Rifampin (2) · Thiotepa (2) · Whole-Body Irradiation (2) · romidepsin (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · AP 1903 reagent (1)
St. Jude Children's Research Hospital (3) · Celgene (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Chinese PLA General Hospital (2) · Ruijin Hospital (2) · Shenzhen TargetRx Co., Ltd. (2) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · Bellicum Pharmaceuticals (1) · BioRay Pharmaceutical Co., Ltd. (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · David Wald (1) · Dialectic Therapeutics, Inc (1)
United States (25) · China (15) · Canada (3) · Italy (2) · Spain (2) · United Kingdom (2) · Australia (1) · Egypt (1) · France (1) · Germany (1) · India (1) · Japan (1) · Russia (1) · South Korea (1) · Switzerland (1)
Ken Takeshita, MD (2) · Swati Naik, MBBS (2) · Adam Lamble, MD (1) · Amit Mahipal, M.D. (1) · Anish Maru, D.M. (1) · Anthony Sung, MD (1) · Benjamin Tomlinson, MD (1) · Bo Jiang, MD (1) · Brandon Triplett, MD (1) · Claudio Brunstein, MD, PhD (1) · Edwin Alyea, MD (1)
PMID 22009536, PMID 31704264, PMID 33022376, PMID 36452492, PMID 37467030, PMID 37925363, PMID 38473278, PMID 38781564, PMID 39293082, PMID 39706761, PMID 41225624, PMID 42495646
2019 (1)